Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | CA3 | P07451 | 1/20 | 0.51 |
| ▸ | CA4 | P22748 | 1/20 | 0.51 |
| ▸ | CA6 | P23280 | 1/20 | 0.51 |
| ▸ | CA5A | P35218 | 1/20 | 0.51 |
| ▸ | CA7 | P43166 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.51 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.51 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 3/20 | 0.36 |
| ▸ | MDM2 | Q00987 | 3/20 | 0.36 |
| ▸ | PER2 | O15055 | 3/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.32 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15185931 | 0.87 | LMNA (0.41) | LMNACA12CA1CA2CA3 | |
| SCHEMBL2617905 | 0.83 | LMNA (0.43) | LMNACA12CA1CA2CA3 | |
| SCHEMBL15185929 | 0.81 | LMNA (0.36) | LMNACA12CA1CA2CA3 | |
| SCHEMBL16358933 | 0.80 | LMNA (0.38) | LMNACA12CA1CA2CA3 | |
| SCHEMBL10164152 | 0.80 | LMNA (0.48) | LMNACA12CA1CA2CA3 | |
| SCHEMBL13075650 | 0.78 | KMT2A (0.38) | LMNACA12CA1CA2CA3 | |
| SCHEMBL4493928 | 0.76 | LMNA (0.58) | LMNACA12CA1CA2CA3 | |
| SCHEMBL564045 | 0.76 | LMNA (0.43) | LMNACA12CA1CA2CA3 | |
| SCHEMBL11561713 | 0.76 | TSHR (0.32) | LMNACA12CA1CA2CA3 | |
| SCHEMBL15186024 | 0.76 | TSHR (0.37) | LMNACA12CA1CA2CA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9399033-B2 | Oligomer-containing pyrrolidine compounds | NEKTAR THERAPEUTICS (US) | 2016-07-26 | — | — | US | disclosed |
| US-20150366842-A1 | OLIGOMER-CONTAINING PYRROLIDINE COMPOUNDS | NEKTAR THERAPEUTICS | 2015-12-24 | — | — | US | disclosed |
| US-9096517-B2 | Oligomer-containing pyrrolidine compounds | NEKTAR THERAPEUTICS (US) | 2015-08-04 | — | — | US | disclosed |
| US-20140288315-A1 | OLIGOMER-CONTAINING PYRROLIDINE COMPOUNDS | NEKTAR THERAPEUTICS | 2014-09-25 | — | — | US | disclosed |
| US-8785661-B2 | Oligome-containing pyrrolidine compounds | NEKTAR THERAPEUTICS (US) | 2014-07-22 | — | — | US | disclosed |
| WO-2010132693-A2 | OLIGOMER-CONTAINING PYRROLIDINE COMPOUNDS | NEKTAR THERAPEUTICS (US) | 2010-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150366842-A1 | OLIGOMER-CONTAINING PYRROLIDINE COMPOUNDS | HTT, PML, NOD2 | LMNA 4479/4885CA12 4537/4885CA1 4290/4885 |
| US-20140288315-A1 | OLIGOMER-CONTAINING PYRROLIDINE COMPOUNDS | HTT, PML, NOD2 | LMNA 4479/4885CA12 4537/4885CA1 4290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.